Table 1 Characteristics of the included studies
References | Country | No. of site | Data collection | No. of patient | % med/chir | Primary outcome | Inclusion criteria | Inclusion period | Severity scorea Mean (sd) or median [IQ] | Number of RBC transfused (mean (sd) or median [IQR]) | Mean Hb level before transfusion | Statistical model | Leukoreduction | % of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Randomized controlled studies | ||||||||||||||
Holst [9] | Denmark | 32 | 998 | 2011–2013 | SII 51 | 100% | 90-day mortality rate: 43% versus 45%, p = 0.44 | |||||||
Cohort studies | ||||||||||||||
Micek [21] | USA | 1 | Prospective | 102 | 60/40 | H death | ss and dotrecogin | 2002–2004 | AII S: 26.3 (5.1) No S: 29.7 (6.1) | S: 1.7 (2.5) No S: 1.3 (2.7) | – | LR | – | 42.2 |
Fuller [52] | USA | 1 | Retrospective | 93 | From ED > 95% | H death | ss | 2005–2008 | AII T: 21.1 No T: 20.3 | 4.56 | – | UNI | – | N (%) (transfused/not transfused) H death: 14 (41.2%); 20 (33.9%); p < 0.05 |
Parsons [12] | USA | 20 | Prospective | 285 | 90/10 | D28 death | S and ALI | 2000–2005 | AIII T: 118 (27) No T: 103 (2) | – | Baseline (Hb)b T: 8.5 (1.4) No T: 9.7 (1.4) | LR | – | D28: transfused: 10 (50%), no transfused: 19 (29%) |
Perner [10] | Denmark | 5 | Prospective | 164 | – | D28 death | ss | 2009–2009 | SII 54 (46–67) | 507 ui of RBCsc [900 ml (490–1405)] | Baseline (Hb) T: 8.58 [7.36–9.28] No T: 9.76 [8.64–10.72] | LR | 100% | D30: 40% |
Park [13] | Korea | 12 | Prospective | 1054 | 100% from ED | D28 death | ss or ss (63.2%) | 2005–2009 | AII No T: 17.4 (7.1) T: 21.2 (7.4) | – | Before transfusion 7.7 (1.2) | COX + PS | 15% | T versus no T D28: 24.3% versus 38.8%; p = 0.007 |
Rosland [11] | Denmark | 10 | Prospective | 213 | 58/42 | D90 death | ss | 2013 | SII 51 (40–65) | mL (median[IQ]) D1: 490 (300–735); D2: 490 (245–490); D3: 245 (245–490); D4:245 (245–245) | D1 (Hb) T: 7.3 (6.8–7.9) No T: 10.0 (8.9–11.1) | LR | 100% | 28-day mortality rate, all 102 (48) |
Sadaka [53] | USA | 1 | Prospective | 396 | – | H death | ss (60%) | 2011–2013 | SOFA T: 8.6 (3.9) Np T:8.4 (3.4) | – | – | LR + matching | – | |
Na [54] | Asia | 8 | Prospective | 556 | 100% from ED | H death | ss or ss (67%) | 2008–2009 | AII 22 (16.27) | – | Baseline (Hb) All 11.6 [9.7, 13.2] | LR | – | In-hospital mortality (%) 166 (29.9) |
Juffermans [24] | Netherlands | Multi | Retrospective | 134 | – | NI | s | 2004–2007 | AII Non T:19 [14–38] T: 24 [145–42] | No infection: 2 [2–5] Infection: 5.5 [2–7] | – | LR | 100% | |
Erbay [25] | USA | 1 | Retrospective | 73 | ICU/Burn unit (%) 47/26 | NI | ICU and KT infection | 1998–2002 | – | – | – | COX | – | |
Iscimen [26] | Turkey | 1 | Prospective | 162 | ALI | ss without ALI | 2004–2007 | AIII ALI:61 [49–72] No ALI:55 [44–64] | – | – | LR | – | ICU death, n (%)ALI:27 (38),no ALI 10 (11), p = 0.001 | |
Plataki [27] | USA | 1 | Prospective | 390 | RIFFLE | ss | 2005–2007 | AIII No AKI: 77 [63–96] AKI: 92 [72–109] | – | Baseline (Hte) AKI: 32 [29–38] No AKI: 31 [27–36] | LR | – | In-hospital mortality rate, n (%) no AKI: 52 (34)versus AKI: 115 (49);p = 0.005 | |